Skip to main content

Stephen Thomas Keir

Professor in Neurosurgery
Neurosurgery, Neuro-Oncology
Box 3624 Med Ctr, Durham, NC 27710
231 Baker House, Durham, NC 27710

Overview


Brain Tumors, Preclinical Testing, Translational Research

Current Appointments & Affiliations


Professor in Neurosurgery · 2021 - Present Neurosurgery, Neuro-Oncology, Neurosurgery
Member of the Duke Cancer Institute · 1992 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications


A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma.

Journal Article Sci Rep · October 23, 2025 Many cancers evade immunosurveillance by downregulating surface major histocompatibility class (MHC)-I. Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes MHC-I degradation and is elevated in glioma. Evolocumab is a clinically approved PCSK9 in ... Full text Link to item Cite

Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma.

Journal Article Mol Cancer Ther · August 1, 2025 Glioblastoma (GBM) is the most common type of malignant central nervous system tumor, and more than 300,000 people are diagnosed with GBM worldwide annually. Based on its recognition as damage by nucleotide excision repair, we now repurpose the DNA labelin ... Full text Link to item Cite

Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics.

Conference Nat Genet · May 2025 The evolution of isocitrate dehydrogenase (IDH)-wildtype glioblastoma (GBM) after standard-of-care therapy remains poorly understood. Here we analyzed matched primary and recurrent GBMs from 59 patients using single-nucleus RNA sequencing and bulk DNA sequ ... Full text Link to item Cite
View All Publications

Recent Grants


McCain/Bayh Glioblastoma Consortium

Clinical TrialProgram Manager · Awarded by Department of Defense · 2025 - 2029

ATRXmutations,innate immune activation and therapeutic vunerabilityin malignant gliomas

ResearchCollaborator · Awarded by National Cancer Institute · 2022 - 2027

PRECLINICAL THERAPEUTIC SCREENING FOR NEW THERAPIES FOR GLIOBLASTOMA MULTIFORME

ResearchInvestigator · Awarded by Jewish Communal Fund · 2022 - 2026

View All Grants

Education, Training & Certifications


Duke University · 2019 M.M.C.i.
University of North Carolina, Chapel Hill · 2004 DrPH
University of North Carolina, Chapel Hill · 2001 M.P.H.